GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MENLO PARK, Calif., Feb. 26, 2025 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units (“RSUs”) underlying an aggregate of 108,450 shares of GRAIL’s common stock to 15 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL’s Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over an approximately four year period, with 25% of the award vesting Feb. 28, 2026, and on each one year anniversary of those respective dates thereafter, subject to continued employment with GRAIL (or any successor to or subsidiary of the Company) through the vesting dates.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302385398.html

SOURCE GRAIL, Inc.

Staff

Recent Posts

WELL Health Announces Delay in Filing of Annual Audited Financial Statements Due to Matter Related to US Subsidiary Circle Medical

VANCOUVER, BC, March 28, 2025 /PRNewswire/ - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF)…

1 hour ago

Antithrombin Blood Test from Siemens Healthineers Now FDA Cleared as a Companion Diagnostic for Qfitlia, a Sanofi Hemophilia Therapy

The assay now can measure antithrombin (AT) activity levels for people treated with Qfitlia Measuring…

7 hours ago

SimonMed Imaging Provides Notice of Security Incident

SCOTTSDALE, Ariz., March 28, 2025 /PRNewswire/ -- SimonMed Imaging confirmed that it experienced a data incident…

7 hours ago

Sohar Health Lands $3.8M to Open the Front Door to Faster, Fairer Care

Kindred Capital backs Sohar Health's mission to remove one of care's biggest hidden barriers and…

7 hours ago

FemTech Leaders Willow and Elvie Unite to Advance the Next Revolution in Maternal Health

Willow acquires Elvie to develop a global multi-category platform offering a diverse range of maternal…

7 hours ago

Dräger and VirtualiSurg receive Obsidian Award for Babyleo XR extended reality simulator.

Award honors groundbreaking innovations in extended reality across reality platforms, spanning hardware, software and content…

7 hours ago